A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)

This study aims to evaluate the combination of GSK525762 with other agents that have been
shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed
to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on
safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with
either abiraterone (Arm A) or enzalutamide (Arm B).